Premium
Combined treatment with sodium butyrate and PD 153035 enhances keratinocyte differentiation
Author(s) -
Leon Carrion Sandra,
Sutter Carrie Hayes,
Sutter Thomas R.
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12333
Subject(s) - filaggrin , sodium butyrate , keratinocyte , cellular differentiation , involucrin , epidermal growth factor receptor , epidermal growth factor , chemistry , cancer research , receptor , microbiology and biotechnology , cell culture , immunology , biology , biochemistry , in vitro , genetics , atopic dermatitis , gene
Epidermal growth factor (EGF) receptor (EGFR) signalling is a critical determinant of keratinocyte proliferation and differentiation in both normal and diseased skin. Here we explore the effects of combined treatment with the differentiation‐promoting agent sodium butyrate (SB) and the EGFR inhibitor (EGFRI) PD153035 on terminal differentiation of normal human epidermal keratinocytes (NHEKs). Cells treated with SB showed increased expression of the levels of mRNA and protein of the differentiation markers filaggrin and transglutaminase 1. Cotreatment with EGF significantly blunted these effects of SB. Combined treatment with SB and PD153035 alleviated these inhibitory actions of EGF, resulting in improved effects of decreased cell growth and increased terminal differentiation, relative to the individual treatments. These results indicate that the combined use of a differentiation‐promoting agent and an EGFR inhibitor may offer an additional approach to the management of hyperproliferative skin diseases.